Health-Related Quality of Life of Patients Receiving Low-toxicity Immunosuppressive Regimens: A Substudy of the Symphony Study
| Autor: | F. Anaya, Federico Oppenheimer, M. Gonzalez-Molina, Jaime Sánchez-Plumed, Domingo Hernández, Francisco B. Ortega, Josep M. Grinyó, Henrik Ekberg, Pablo Rebollo |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Daclizumab Time Factors Health Status medicine.medical_treatment Antibodies Monoclonal Humanized chemistry.chemical_compound Quality of life Adrenal Cortex Hormones Internal medicine medicine Humans Health related quality of life Transplantation Creatinine Dose-Response Relationship Drug business.industry Antibodies Monoclonal Immunosuppression Middle Aged Mycophenolic Acid Health Surveys Kidney Transplantation Tacrolimus Surgery chemistry Immunoglobulin G Sirolimus Toxicity Cyclosporine Quality of Life Female business Immunosuppressive Agents Follow-Up Studies medicine.drug |
| Zdroj: | Transplantation. 87:1210-1213 |
| ISSN: | 0041-1337 |
| Popis: | Objective. To evaluate health-related quality of life (HRQoL) in patients with different low-toxicity regimens post-transplantation. Methods. One hundred fifty-six patients were randomized to standard-dose cyclosporine A (CsA), mycophenolate mofetil, and corticosteroids or daclizumab induction, mycophenolate mofetil, and corticosteroids with a low dose of CsA, tacrolimus (Low-Tac), or sirolimus. SF-36 Health survey was completed at baseline, 3, 6, and 12 months. Results. There were no differences between groups in SF-36 at baseline or at month 12. Low-Tac showed higher scores at month 3 than standard-dose CsA and low dose of CsA. Patients with serum creatinine less than or equal to 1.5 mg/mL had better HRQoL at 6 and 12 months. Proportion of these patients was higher in Low-Tac at 6 months. Physical component summary of Patients increased during follow-up, but mental component summary did not. Patients with acute rejection showed lower mental component summary at 6 months. Conclusions. No HRQoL differences were identified among groups, but the low-dose Tac group showed the fastest improvement. (Less) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|